Key Points
- Director Michael Malafronte bought 8,890 shares of Adtalem (NYSE:CVSA) on March 11 at an average price of $100.94 per share for a total of $897,356.60, increasing his stake to 25,395 shares (a 53.86% rise).
- CVSA recently traded at $104.60, has a 52-week range of $86.97–$156.26, a market cap of about $3.61 billion and a P/E of 15.36; the company reported $2.43 EPS and $503.39 million in revenue for the quarter.
- Analyst sentiment is generally positive with an average rating of "Buy" and a consensus target price of $170, amid recent notes ranging from Strong Buy to Hold (Zacks upgraded to Strong-Buy; Barrington set a $170 target).
Adtalem Global Education Inc. (NYSE:CVSA - Get Free Report) Director Michael Malafronte purchased 8,890 shares of Adtalem Global Education stock in a transaction dated Wednesday, March 11th. The stock was acquired at an average price of $100.94 per share, for a total transaction of $897,356.60. Following the completion of the acquisition, the director owned 25,395 shares of the company's stock, valued at approximately $2,563,371.30. This trade represents a 53.86% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Adtalem Global Education Price Performance
Shares of CVSA stock traded up $0.76 on Friday, reaching $104.60. 80,927 shares of the company's stock were exchanged, compared to its average volume of 432,512. Adtalem Global Education Inc. has a 52 week low of $86.97 and a 52 week high of $156.26. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.68 and a current ratio of 0.68. The firm has a market capitalization of $3.61 billion, a P/E ratio of 15.36, a P/E/G ratio of 0.85 and a beta of 0.72.
Adtalem Global Education (NYSE:CVSA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $2.43 EPS for the quarter. Adtalem Global Education had a return on equity of 20.24% and a net margin of 13.41%.The company had revenue of $503.39 million for the quarter.
Wall Street Analyst Weigh In
CVSA has been the topic of several recent analyst reports. Weiss Ratings assumed coverage on shares of Adtalem Global Education in a research note on Wednesday, February 25th. They issued a "hold (c+)" rating on the stock. Zacks Research upgraded shares of Adtalem Global Education from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 24th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $170.00 target price on shares of Adtalem Global Education in a research report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Adtalem Global Education has an average rating of "Buy" and a consensus target price of $170.00.
View Our Latest Stock Analysis on CVSA
Adtalem Global Education Company Profile
(
Get Free Report)
Adtalem Global Education (NYSE: CVSA) is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.
Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
